

REVIEW ARTICLE

A new era of atopic eczema research: Advances and highlights

Claudia Hülpmusch^{1,2,3}  | Andreas B. Weins⁴  | Claudia Traidl-Hoffmann^{1,2,3,5}  | Matthias Reiger^{1,2,3} 

¹Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany

²Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany

³CK CARE – Christine Kühne Center for Allergy research and Education, Davos, Switzerland

⁴Department of Dermatology, Faculty of Medicine, University of Augsburg, Augsburg, Germany

⁵ZIEL, Technical University of Munich, Freising, Germany

Correspondence

Claudia Traidl-Hoffmann, Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, and Helmholtz Zentrum München, Neusäßler Str. 47, D-86156 Augsburg, Germany. Email: claudia.traidl-hoffmann@med.uni-augsburg.de

Abstract

Atopic eczema (AE) is an inflammatory skin disease with involvement of genetic, immunological and environmental factors. One hallmark of AE is a skin barrier disruption on multiple, highly interconnected levels: filaggrin mutations, increased skin pH and a microbiome dysbiosis towards *Staphylococcus aureus* overgrowth are observed in addition to an abnormal type 2 immune response. Extrinsic factors seem to play a major role in the development of AE. As AE is a first step in the atopic march, its prevention and appropriate treatment are essential. Although standard therapy remains topical treatment, powerful systemic treatment options emerged in the last years. However, thorough endotyping of the individual patients is still required for ideal precision medicine approaches in future. Therefore, novel microbial and immunological biomarkers were described recently for the prediction of disease development and treatment response. This review summarizes the current state of the art in AE research.

KEYWORDS

atopic dermatitis, biomarkers, personalized medicine, therapy

1 | INTRODUCTION

Atopic eczema (AE) or atopic dermatitis (AD) is an inflammatory skin disease with involvement of genetic, immunological and environmental factors which are highly interconnected.^{1,2} The heterogenic disease can be separated into different phenotypes and clinical presentations defined by the ethnicity, disease onset, disease severity, chronic vs acute, intrinsic vs extrinsic (IgE level), paediatric vs adult and inflammatory signature.³⁻⁵ A common feature of all subtypes is a tremendous psychosocial burden for all patients with AE.⁶ Prevalence varies by area and is reported to be 15–20% in children in Europe, persisting in up to 5–10% of adults.⁷⁻⁹ Although severe cases are less abundant than mild or moderate disease pattern, 2% of affected children are severely suffering.^{7,9} Therefore, AE remains to be a high and even increasing socio-economic burden in the United States and in Europe,^{10,11} whereas slightly decreasing numbers were reported over the last few years in Japan.¹² Children often overcome atopic eczema, but set off on the so-called ‘atopic march’,

that is begin a classic ‘allergy career’. Scientifically, AE is a risk factor for the development of allergies. These are primarily type I allergies with clinical features such as hay fever and asthma. Allergies are increasingly becoming a widespread disease. Currently, almost every fourth person in Europe suffers from symptoms such as asthma or hay fever and the associated restrictions in everyday life or at work. For society, the reduced ability to perform at school, university and at work means great socio-economic damage.^{13,14}

2 | ATOPIC ECZEMA AS AN ENVIRONMENTAL DISEASE

The picture of the reasons for the rapid increase in allergies and atopic diseases remains incomplete to this day. For sure, it cannot be explained by genetics alone.¹⁵ In fact, AE can potentially be seen as an environmental disease occurring in susceptible individuals.¹⁶⁻¹⁸ A variety of intrinsic and extrinsic risk factors were identified to influence

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

AE development and exacerbation (Figure 1).¹⁹ Intrinsic risk factors for AE include parental atopic history, filaggrin (FLG) mutations, polysensitization, decreased short-chain fatty acids in the gut of children, and underlying medical conditions as keratoconus.^{20–25} However, extrinsic factors as low microbial exposure and diversity, antibiotic exposure, urban environment, tobacco smoke exposure, stress, food and pollutants are as important for AE development.¹⁶ The lower and later exposure to microbes is described by the 'hygiene' or 'old friends' hypothesis and is associated with increased allergy prevalence.^{26–28} The relationship between host and microbes is symbiotic and bacteria shape essential biological functions such as the development of a tolerogenic immune response towards commensals.²⁹ In line, the prevalence of AE was reported to be higher in urban than in rural areas.³⁰ The hygiene theory could be supported recently in a birth cohort—siblings, infections and pet—especially dog keeping—were protective for AE.^{28,31} However, contradicting results exist on the influence of dog and cat ownership on disease development.^{32,33} Also, caesarean section birth with lower microbial exposure could recently not be confirmed to have a higher risk for AE than vaginal delivery,³⁴ whereas very preterm birth even seems to be associated with decreased risk for AE development.^{20,21} A deeper understanding of the complex interplay between microbes and host is still needed.³⁵ Another environmental factor is the surrounding climate in a given location, a combination of temperature, and precipitation and therefore UV exposure and humidity.¹⁶ Although contradicting reports exist on the influence of the single factors on AE development and exacerbation, they seem to be worth further investigation, especially in times of climate change.^{16,36} These factors also influence sweat production, which promotes itch in AE.³⁷ Also, water hardness and detergent usage impact AE.^{9,38} The patient's residence also determines the exposure to airborne trigger factors as aeroallergens and air pollutants which are associated with AE development and exacerbation. Especially, aeroallergens from house dust mite, pollen and pet dander caused positive patch tests and delayed cutaneous response in AE patients to a higher extent than in healthy controls.³⁹ One major component of environmental air pollutants is Diesel exhaust particles, which triggers an itch-scratch response by binding to the aryl hydrocarbon receptor (AhR).^{40–42} Children seem to be more vulnerable than adults to pollution as an AE exacerbation trigger.⁴³ The stress level coming from the psychosocial environment is another extrinsic factor, which is correlated with disease symptom severity and exacerbation,⁶ leading to a vicious circle as AE is a strong psychological burden for patients.^{44,45} In line, psychological interventions had a positive effect on AE severity in a meta-analysis and were also associated with other allergic diseases.^{46,47}

3 | ATOPIC MARCH AND DISEASE PERSISTENCE

Not in all cases of childhood AE, the disease persists to adulthood. Risk factors for persistence are predicted by disease severity and vascular endothelial growth factor (VEGF) serum levels at three years⁴ as well as by early-onset and high IL-13 levels.^{48,49} Furthermore, the risk

Milestones

- Environmental risk factors are important in AE development
- Recognition of the complex interplay between environment and host-microbe
- Discovery of biomarkers as TARC and the microbiome for AE progression
- Biologics strongly improve symptom severity
- Recognition of the disease diversity is reflected in the variety of novel therapy targets

Outlook

- Targeting *S. aureus* or its communication system as leverage point for local AE treatment
- *S. aureus* vaccines could improve the patient situation
- Efficacy of AE prevention, for example with emollients and pre- and probiotics is still controversial but could be an essential tool to stop the atopic march
- Investigation of active modulation of the skin barrier (eg pH) and the immune system (eg Vitamin D3, sport, food) should be in focus
- Time frame and trigger factors for AE development must be further investigated

to develop allergic rhinitis—especially in untreated AE⁴⁹— or adult-onset asthma is significantly higher in patients with allergic diseases and AE.⁵⁰ Therefore, AE is claimed to be the first step of the so-called atopic march.⁵¹ Underlying skin barrier defects in AE facilitate the penetration of allergens and irritants and can thereby lead to food allergy, allergic rhinitis, and/or allergic asthma.¹³ A signature of eight genes (CLC, EMR4P, IL5RA, FRRS1, HRH4, SLC29A1, SIGLEC8 and IL1RL1) identifies multimorbidity for asthma, rhinitis and AE, suggesting that multimorbidity is mechanistically different to single allergic diseases.⁵² The fact that AE itself is a risk factor for the development of allergies also means that the treatment of this chronic inflammatory skin disease can be a prevention of other atopic diseases.

4 | BASIC MECHANISMS AND POTENTIAL TARGETS

4.1 | Disturbed skin barrier (FLG, pH, microbiome)

The skin barrier in AE is disturbed on multiple levels, including physical, chemical, immunological, neurologic and microbial components.¹

Martin et al. recently summarized genetic risk factors for AE, many of them belonging to extracellular matrix components and its modulators (eg FLG, COL5A3, COL6A6 and MMP9, TMEM79).^{53,54} A variety of AE mice models are used to investigate skin barrier defects, among them FLG flaky tail (ft)/ft mice,⁵⁵ Hrrn^{-/-} mice⁵⁶ and




FIGURE 1 Risk and protective factor for atopic dermatitis. Known extrinsic risk factors (red) and protective factors (blue) for atopic dermatitis are summarized in this figure

TMEM79^{-/-} mice.⁵⁴ One major genetic predisposition for the development of AE are loss-of-function mutations in the skin barrier gene filaggrin.⁵⁷ Degradation products of histidine-rich filaggrin support the healthy skin barrier as natural moisturizing factors (NMF) and simultaneously maintain an acidic skin pH.⁵⁸ The skin pH in AE and especially AE lesions was reported to be increased.⁵⁹ In line, an acidic skin pH is associated with low scaling and high hydration, whereas alkaline skin pH is associated with skin barrier dysfunction and decreased stratum corneum integrity.^{60,61} Alkalinization of the skin pH directly modulates the activity of the stratum corneum located serine protease kallikrein 5 (KLK5) which has the ability to degrade cell junction proteins, leading to barrier dysfunction and itch.⁶² Recently, exogenous mutations in the KLK5 inhibitor Lympho-epithelial Kazal-type-related inhibitor (LEKTI) were associated with AE, supporting the importance of protease activity in the disease.⁶³ Furthermore, the lipid composition of the skin is abnormal in AE. Changes in ceramides and free fatty acids were reported, the latter correlating with the skin microbiome composition.^{64,65}

A skin microbiome dysbiosis towards *Staphylococcus aureus* and decreased microbial diversity is another hallmark of AE.⁶⁶ The intrinsic and extrinsic factors shaping the skin microbiome are complex and yet poorly understood.³⁵ However, several factors relevant in AE are known to influence the microbiome. The acidic skin pH of healthy skin for example limits the growth of harmful skin bacteria as *S. aureus* and enhances the growth of the commensal *S. epidermidis*.^{67,68} Genetics also shape the skin microbiome as recently shown in a mouse model: wild-type and Flg ft/ft mice significantly differed in the skin microbiome composition, revealing less diversity with an increased staphylococci colonization.⁵⁵ In this study, AE did not develop under germ-free conditions but was dependent on microbial colonization and subsequent IL-1 β induction.⁵⁵ Both alpha-diversity and *S. aureus* abundance correlate with disease severity. However, this association seems to depend on the skin site and could be shown for the thigh but not the back of AE patients in a recent study.⁶⁹ Not only the presence of *S. aureus* but also capability of *S. aureus* strains to produce biofilm and toxins is associated




FIGURE 2 Leverage points for (future) atopic dermatitis therapies. In atopic dermatitis, the skin barrier is disturbed on multiple levels and could be used for atopic dermatitis treatments in future. AMP, Antimicrobial peptides; IL, Interleukin; miRNA, micro RNA; NMF, Natural moisturizing Factors; Th2, T-helper 2 TLR, Toll-like receptor

with AE severity.^{66,70,71} *S. aureus* activates the immune system in AE among others by the expression of proteases, toxins, superantigens and other virulence factors^{66,72} (Figure 2). Interestingly, cigarette smoke redirects *S. aureus* towards virulence factor associated with persisting infection and could therefore explain the avoidable risk factor of tobacco smoke for AE.^{25,73} The virulence factors trigger a vicious cycle in AE. The stimulation of the immune system shapes the inflammatory environment, the expression of IL-31 causes itch and the resulting scratching further damages the skin barrier. The complex interaction between *S. aureus* and the innate and adaptive immune system has been nicely summarized by Yoshikawa et al 2019.⁶⁶

In the context of itch and scratch response, sensory neurons are important.⁷⁴ However, the nervous system is not only responsible for pruritus, but also modulates the immune response in AE.⁷⁵

4.2 | Immune system

The disturbed skin barrier in AE facilitates the entrance of allergens which are presented by antigen-presenting cells in the lymph nodes to naïve T cells, which in the presence of, for example, thymic stromal lymphopoietin (TSLP) differentiate into allergen-specific T-helper cells. These cells release IL-4, IL-13 and IL-5—a major hallmark in AE—which lead to even stronger epithelial skin barrier disruption by downregulation of filaggrin and claudins and recruitment of eosinophils.⁷⁶⁻⁷⁹ Recently, vitamin D3 was found to directly influence skin dendritic cells to drive Th2 response independently of thymic stromal lymphopoietin.⁸⁰ Basophils were identified as one of the main producer of IL-4 identified in mice and are consequently a potential therapeutic target.⁸¹ In turn, in vitro stimulation of eosinophils with IL-4 and IL-13 lead to an overexpression of the histamine-receptor H4R whose antagonists are already in clinical trials for

AE.⁸²⁻⁸⁴ Eosinophils, mast cells, dermal dendritic cells, natural killer cells and macrophages were found in significantly higher numbers in biopsies from lesional AE skin.⁸⁵

The innate immune system of the skin consisting of biochemical and cellular components is the first line of defence and senses and regulates the skin microbiome.^{2,86} Multiple mutations in the innate immune system pathways (eg ADAM33, MIF, MMP9, ORM2, RETN and TLR2),⁵³ as well as a lack of antimicrobial peptides (AMPs) were reported in the context of AE. The AMPs LL-37, human beta-defensin-2 (hBD-2) and hBD-3 are downregulated in AE skin lesions compared to psoriasis lesions.^{87,88} A deficiency of antimicrobial peptides in the sweat of AE patients correlates with an impaired innate defence in AE.⁸⁹ Interestingly, AMPs are not only produced by the skin itself, but also by microbes.⁹⁰ Not only AMPs but also pattern recognition receptors like Toll-like receptors (TLRs) reveal polymorphisms and aberrant expressions in AE, among them TLR2, which is capable of sensing Gram-positive staphylococci as *S. aureus* and TLR9.^{91,92} Interestingly, TLR2, which has been associated with severe forms of AE, can both lead to amplification of cutaneous inflammation and severe immunosuppression in combination with TLR6.⁹³ *S. aureus* strains of AE patients but not laboratory strains were reported to accumulate in keratinocytes and induce IL-1alpha via TLR9,⁹⁴ further exacerbating the inflammation. It has been shown that different staphylococcal antigens cause individual response on the specific IgG and IgA production,⁹⁵ but also interactions between IgE and staphylococcal antigens like SEA, SEB or fibronectin have been reported to play a role in disease development by activating specific IgE- and T cell-mediated immune responses.^{96,97} In addition, it is also known that *S. aureus* can evade the T cell-mediated response at different steps and evades immunological memory which may have implications on vaccine development.⁹⁸

5 | DIAGNOSIS AND CLINICAL ASSESSMENT OF SEVERITY

The American Academy of Dermatology (AAD) developed consensus criteria for clinicians for the diagnosis of AE especially in young children consisting of three sub-categories of essential, important and associated features.⁹⁹ Novel biomarkers to distinguish early in life between AE and hyper IgE syndrome (HIES) were recently reported, specifically, an upregulation of CXCL10 and TNF- α and a downregulation of EGF for HIES compared to AE patients.¹⁰⁰ AE severity (from mild to severe) can be elucidated by validated scores like Scoring atopic dermatitis (SCORAD) or Eczema Area and Severity Index (EASI) which are useful for clinical trials.¹⁰¹ For daily assessment of treatment success, the novel and quick to fill atopic dermatitis score 7 (ADS7) has been proposed, which considers lesions and discomfort as itch and quality of life.¹⁰²

6 | BIOMARKERS FOR DISEASE SEVERITY

Multiple factors have been described to correlate with AE severity. Measurement of NMFs via Raman spectroscopy has been shown to be a reliable clinical marker for AE and can be used when deciding for treatment.¹⁰³ To objectively measure skin integrity, electrical impedance spectroscopy (EIS) measurements can be performed.¹⁰⁴ EIS measurements could be used to distinguish between healthy, AE non-lesional and lesional skin, correlated positively with disease severity, and correlated inversely with biomarkers associated with inflammation, making it a more reliable and sensitive tool for in vivo barrier disruption detection than transepidermal waterloss (TEWL) measurements.¹⁰⁵ Also, the microbiome can be used as a marker for disease severity, assess risk-prone state of skin, and predict treatment response in children across human populations.¹⁰⁶ Among them are bacterial factors as *S. aureus* abundance, which has been correlated with disease severity, but also as a biomarker for disease worsening.^{67,107} However, before the skin microbiome can be widely used as clinical biomarker, a standardized method would be required for microbiome analysis.¹⁰⁸ Also immunological factors are associated with disease severity, for example thymus and activation-regulated chemokine (TARC) detected in dried blood spots.¹⁰⁹ A biomarker signature (p-EASI) based on multiple immunological biomarkers reliably predicts disease severity.^{110,111} Local, non-invasive sampling of the skin would be well-tolerated and allows a thorough analysis of the complex interplay of the skin barrier, the immune system and microbes in vivo. Allergy-associated genes and gene-variants are now listed in the database *AllergyGenDB* which thus can be used for hypothesis generation in research.¹¹² Thorough endotyping of AE patients would be very efficient and cost-effective for treatment.¹¹³ One possible method would be tape stripping, which successfully revealed multiple AE markers in a current study.¹¹⁴ Biomarkers are essential for diagnosis and personalized and tailored therapy, especially in a multifaceted disease as AE.¹¹⁵

7 | THERAPY

AE therapy has undergone a true revolution in recent years. We are on the way to being spoiled for choice in deciding which systemic therapy to use. What remains to be seen, however, is which subtype of AE will respond to which new targeted drug. Tailored treatment strategy in AE depends on the individual patients' age, history and disease severity, evaluated by assessing both objective and subjective factors.^{116,117} Interestingly, unique T-cell subsets and cytokine patterns in paediatric compared to adult AE patients urge for age-specific therapies.^{116,118} Considering the multidimensional nature of AE, effective disease management incorporates different pillars of treatment. Besides basic skin care and individual pharmacological approaches, patient education and self-management strategies that address social and environmental factors have to be included—not only to optimize individual outcomes, but also to reduce unnecessary costs associated with the management of AE.¹¹⁹ The knowledge and therapy options expand rapidly in AE and the current standards for diagnosis and therapy are nicely summarized by Wollenberg et al.¹²⁰ Interestingly, a recent study has shown that patients self-reported disease severity seems to be correlated with treatment satisfaction of AE patients.¹²¹

7.1 | Local therapy

With respect to the skin barrier dysfunction as a pathognomonic factor in the pathogenesis of AE, emollient therapy marks an essential element in the disease management: Application of emollients in adequate amount (>250g/week) and frequency (at least once, better twice a day; additionally, after any skin cleansing) is necessary to enhance the integrity of epidermal barrier and consequently reduce the susceptibility for irritation and inflammation of the skin. Interestingly, a pilot study has recently shown greater efficacy of a novel trilipid cream (a 3:1:1 ratio of ceramides, cholesterol and free fatty acids) than a regular paraffin-based emollient considering the reduction of transepidermal water loss.¹²²

Topical anti-inflammatory treatment is still the mainstay of mild-to-moderate forms of AE and especially acute exacerbations due to a reduction of pruritus and inflammation and restoration of skin barrier function. Both topical corticosteroids (TCS) and calcineurin inhibitors (TCI) have shown to be safe and effective for reducing acute flares and risk of relapse if applied in an appropriate intensity and dosage, especially in a proactive setting (eg twice weekly usage on predilection areas). Concomitant use of emollients in an appropriate amount has proved a steroid-sparing effect.^{123,124} Besides their anti-inflammatory properties, positive cutaneous microbiome effects have been shown for TCS and TCI.

Promising new topical agents that inhibit key regulators of pro-inflammatory signals are in clinical development (eg Janus Kinase Inhibitors) or have been recently approved (eg selective Phosphodiesterase 4 Inhibitor Crisaborole) (see Table 1). Further

TABLE 1 Currently available and upcoming treatment options

	Target/mode of action	stage	Efficacy to placebo	Treatment duration
Systemic treatment				
Abrocitinib	JAK-1 Inhibition	Unapproved, 2 RCT	Superior to placebo (EASI, IGA)	12 weeks
Apremilast	PDE-4-Inhibition	Unapproved, 1 RCT	Superior to placebo (EASI, DLQI)	12 weeks
Azathioprine	Inhibition of purine synthesis	Unapproved, 3 RCT	Superior to placebo (SASSAD, pruritus/sleep disturbance VAS, DLQI)	12 weeks – 5 years
Baricitinib	JAK-1/JAK-2-Inhibition	Approved	Superior to placebo (EASI, SCORAD,IGA; DLQI, POEM, NRS itch)	16 weeks
Cyclosporine A	Calcineurin-Inhibition	Approved	Superior to placebo in nonvalidated and validated scores (EDI, pruritus/sleep loss VAS, SASSAD, UKSIP)	6–52 weeks
Corticosteroids (prednisolone, beclomethasone, flunisolide)	Interaction with the glucocorticoid receptor (genomic, non-genomic)	Unapproved, 85 RCT	Superior to placebo in nonvalidated scores,	4–52 weeks
Dupilumab	Inhibition of IL-4Ra: blockade of IL-4/IL-13-signalling	Approved	Superior to placebo (EASI, IGA, NRS itch, POEM, DLQI, cDLQI, GISS, QoLIAD)	4–76 weeks
Lebrikizumab	Binding of IL-13: Blockade of IL-13 signalling	Unapproved	Superior to placebo (EASI, IGA)	12–16 weeks
Mepolizumab	IL-5-Inhibition	Unapproved, 1 RCT	Not superior to placebo (SCORAD, VAS pruritus)	4 weeks
Methotrexate	Antimetabolite (antifolate): inhibition of DNA, RNA, thymidylate and protein synthesis	Unapproved, 3 RCT	No trials with comparison to placebo; superior to azathioprine (SCORAD), cyclosporine (SCORAD)	12 weeks - 5 years
Nemolizumab	Binding of IL-31-receptor-alpha-unit	Unapproved, 2 RCT	Superior to placebo (EASI, IGA, NRS)	24–64 weeks
Omalizumab	Depletion of IgE	Unapproved, 2 RCT	Conflicting results: superiority (EASI, SCORAD, DLQI); non-superiority (EASI, SCORAD, IGA)	16–24 weeks
Tralokinumab	Binding of IL-13: Blockade of IL-13 signalling and regulation	Unapproved, 3 RCT	Superior to placebo (EASI)	12 weeks
Upadacitinib	JAK-1-Inhibition	Unapproved, 1 RCT	Superior to placebo (EASI, SCORAD, NRS itch)	16 weeks

Age	Common reported treatment-emergent adverse effects	Comment	Guideline recommendation
>12 years, adults	Pneumonia, eczema herpeticatum, herpes simplex infections, gastrointestinal complaints, thrombocytopenia		No statement
Adults	Cellulitis	Already approved for psoriasis, psoriasis arthritis, Behcet's disease	Not recommended
>16 years, adults	Myelosuppression, hepatotoxicity, gastrointestinal adverse effects, infections, headache	Disease-modifying drug in auto-immune diseases	May be considered as off-label use for refractory and severe cases of AD after exhaustion or drop-out of other treatment options (dupilumab, ciclosporin)
Adults	Nasopharyngitis / polyps, upper respiratory tract inflammation, elevation of creatine phosphokinase levels, headache	Already approved for rheumatoid arthritis	Not yet
>7 years, adults	Nephrotoxicity, hypertension, gastrointestinal adverse effects, headache, hypertrichosis, upper respiratory tract infection	Prevention of graft-versus-host disease, prevention of rejection of transplants	May be considered for short to medium-term treatment in children (off-label), adolescents and adults with refractory and severe AD
Children, adults	Exacerbations of eczema	Allergic reactions among others	Due to long term adverse effects only for short term treatment in severe cases of paediatric or adult AD
Children, adults	Conjunctivitis, injection site reactions, upper respiratory infection, nasopharyngitis, headache, herpes simplex infection	Also approved for asthma, chronic sinusitis with nasal polyposis	May be recommended for children (>6 years) / adults with chronic and severe / chronic and moderate to severe AD
Adults	No serious or dose-dependent TEAE		No statement
Adults	Not reported	Approved for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis	
Children, adults	Hepatitis, gastrointestinal side effects	Disease-modifying drug in auto-immune diseases, chemotherapy	May be considered as a off-label use for chronic and severe cases of AD.
Adults	Nasopharyngitis, upper respiratory tract infection		No statement
Children, adults	Abdominal pain, nausea, allergic reactions, exacerbation of eczema	Approved for chronic urticaria, asthma	Not recommended
Adults	Headache, upper respiratory tract infection		No statement
Adults	Upper respiratory tract infection, exacerbation of AD, acne, arrhythmia, dental disease, appendicitis	Approved for rheumatoid arthritis	No statement

(Continues)

TABLE 1 (Continued)

	Target/mode of action	stage	Efficacy to placebo	Treatment duration
Ustekinumab	IL-12-/IL-23p40-antagonist	Unapproved, 2 RCT	Non-superiority to placebo (EASI, SCORAD, DLQI, ADIS)	12–24 weeks
Topical treatment				
Crisaborole	PDE4B Inhibition	Approved (US)	Superior to vehicle (ISGA)	4 weeks
Ruxolitinib	JAK-1/JAK-2-Inhibition	Unapproved	Superior to vehicle (EASI, IGA, NRS itch)	4 weeks

Note: Data are showing topical and systemic treatment options adapted from previous literature.^{117,135–138}

Abbreviations: SASSAD, Six area; six sign atopic dermatitis; EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment; ISGA, Investigator's Static Global Assessment; (c)DLQI, (Children's) Dermatology Life Quality Index; VAS, Visual Analogue Scale; SCORAD, SCORing Atopic Dermatitis; NRS, Numeric Rating Scale; EDI, Eczema Disability Index; POEM, Patient Oriented Eczema Measure; GISS, Global Individual Sign Score; QoLIAD, Quality of Life Index for Atopic Dermatitis; ADIS, Atopic Dermatitis Itch Scale; TEAE, Treatment-Emergent Adverse Events.

real-life studies will have to show their potential role in management of AE.¹²⁰

In many cases, adequate control of AE can be achieved by topical treatment options, if applicable even in combination with phototherapy (eg UVB and UVA-1). However, if local therapy remains insufficient, or in case of severe or persistent disease, systemic treatment is indicated.

7.2 | Skin barrier as a potential target for treatment—new developments

The disturbed skin barrier offers a variety of novel leverage points for future AE treatment. One option would be to tackle the dysbalanced skin microbiome with pre- and probiotics. A study achieved positive results by applying heat-treated *Lactobacillus johnsonii* NCC 533 on AE skin.¹²⁵ The topical microbiome transplant of *Roseomonas mucosa* from healthy participants to AE patients improved AE severity in a clinical I/II safety and activity trial.¹²⁶ As *S. aureus* is one of the driving factors in AE, multiple strategies to control *S. aureus* growth emerged. An active reduction of *S. aureus* could be achieved with competing coagulase-negative staphylococci (CoNS) which produce antimicrobial peptides against *S. aureus*.¹²⁷ Furthermore, it could be shown that CoNS could inhibit quorum sensing and thereby virulence of *S. aureus*.^{128,129} Another strategy is to shift the microenvironment towards unfavourable conditions for *S. aureus*. As acidic and alkaline pH seem to limit the growth of *S. aureus* in vitro and in vivo, acidification of the skin could be one strategy. However, sustained acidification of the skin was not yet successful.^{67,130} Therefore, more acidic products, well-buffered products or a more continuous application of the emollient could be beneficial. Dilute bleach baths also do not reduce *S. aureus* load and AE severity in vivo or in vitro.^{67,101,130,131} Contrastingly, removal of *S. aureus* by

UVB is known to be quite successful.¹³² An exciting new strategy in AE management could also be an anti-*S. aureus* vaccine.¹³³

7.3 | Systemic therapy

For severe forms of AD or cases that do not respond adequately to topical treatment, systemic therapy should be considered. In practice, several systemic anti-inflammatory treatment options are established for treating AE: Until approval of dupilumab in 2017 and baricitinib in 2020, cyclosporine has been considered as first-line option over many years. Other immunosuppressive drugs (eg azathioprine, methotrexate) have been also used with good response, but off label and/or as second-line therapy, in AE.^{134,135} As stated above, many different cellular and molecular effectors are involved in AE. The expanding knowledge of this complex type 2 immunological background of AE leads to new developments of new cytokine-directed treatment options that are currently under investigation (Table 1).^{117,135–138}

The European Academy of Allergy and Clinical Immunology (EAACI) AE guideline group nicely summarized evidence on systemic treatments for AE identifying the need for trials comparing novel systemic treatments with conventional therapies.¹³⁵

Besides skin inflammation and barrier dysfunction, itch represents a cardinal symptom of AE. For a long time, histamine has been assumed to be the main mediator of itch. Antihistamines have been commonly used for reducing itch in AE patients, but with conflicting evidence. Two Cochrane studies have recently shown that antihistamines have no or just a limited antipruritic effect.^{139,140} It is important to note that recent research has resulted in progress in understanding the complex pathophysiology of atopic itch, from which more specific treatment options will arise perspectively.¹⁴¹

Age	Common reported treatment-emergent adverse effects	Comment	Guideline recommendation
Adults	Nasopharyngitis, contact dermatitis, eczema herpeticatum	Approved for psoriasis, psoriasis arthritis, Crohn's disease, ulcerative colitis	Treatment with ustekinumab may be considered in cases of coincidence of AD with psoriasis, psoriasis arthritis, rheumatoid arthritis or chronic inflammatory bowel disease
>2 years, adults	Application site stinging/burning/pain	Suitable as a steroid-sparing agent, but questionable cost-effectiveness	No statement
Adults	Studies for children are underway		No statement

7.4 | New developments in systemic treatment options

Several more biologics and small molecules interfering with key mediators of AE are currently in development and may contribute to tailored therapeutic approaches in future.⁷⁸ An interesting approach to improve AE in patients unresponsive to extensive therapy is, to use repetitive transient reductions of total IgE, which lead in a small number of patients to long-lasting improvement of AE with improvement of both clinical parameters as well as the quality of life.¹⁴² Allergen-specific immunotherapy (ASIT) is currently not recommended as a common treatment approach.¹³² But ASIT against animal dander has been shown to reduce specific IgE in AE patients and could be effective treatment option for patients with respiratory allergic comorbidities.¹⁴³ Additionally, downregulatory strategies for the immune system are under investigation. CD300a expression has a downregulatory role in AE (mice), this could be an anti-inflammatory strategy.⁸⁵ The immune system in epithelial cells is posttranscriptional regulated by miRNAs.¹⁴⁴ Among others, miR-10a-5p has been identified to modulate AE targets.¹⁴⁵ L-type amino acid transporter 1 (LAT1) is critical for activating human and mouse T cells and its inhibition reveals a potential new target for AE treatment.¹⁴⁶

It is important to increase the knowledge about the complex mechanisms influencing AE and therefore a combination of patient information correlated with biomaterial analysis and in vitro testing is needed. The CK-CARE program will contribute to identify and validate new and reliable biomarkers for precision medicine.¹⁴⁷

8 | PREVENTION

As the underlying skin barrier defects observed in AE are the first step in the atopic march, the prevention of AE is very appealing—and

especially in families with known risk factors—highly important. As emollients are the primary management strategy in AE, emollient application at early age is an obvious prevention method for AE. Contradictory data exist on its efficiency. Whereas earlier studies hinted towards a highly effective approach for AE prevention in neonates, this could not be confirmed in recent studies where no evidence was found that daily emollients had a preventive effect in neither a population-based nor a high-risk cohort.¹⁴⁸⁻¹⁵³ One factor for the conflicting results could be the formulation of the ointment. Ceramide-based emollients are more efficient in reducing the TEWL, whereas peanut-oil based ointments were reported to be a facilitator for allergy.^{122,154} Due to the barrier defect, emollient components can most likely cross the skin barrier more easily in AE. Even though early supplementation of peanut, cow milk, wheat and eggs was not protective for AE,¹⁴⁹ a diverse diet and cheese consumption seem to be beneficial, possibly due to the high microbial diversity found in cheese.^{155,156} In the same direction, pre- and probiotics are potentially protective for AE development.¹⁵⁷ Although prebiotics are non-digestional ingredients which promote beneficial bacteria such as *Bifidobacterium* and *Lactobacilli*, probiotics are active bacteria which are beneficial for human health.^{158,159} Among them are *Bifidobacterium* and *Lactobacilli*, Gram-positive, anaerobic bacteria which are potentially capable of producing lactic-acids and antimicrobial substances and bacteriocins, limiting potentially pathogenic gut bacteria.¹⁵⁷ The data on the efficiency of pre- and probiotics are highly controversial, likely due to differences in type or mixture of strains.¹⁶⁰ Orally applied prebiotic *Escherichia coli* and *Enterococcus faecalis* in children were ineffective in AE prevention.¹⁶¹ Contrarily, the administration of probiotics during pregnancy has been confirmed to prevent AE of the children in a meta-analysis of 19 studies.¹⁶² Continuation of probiotics during breastfeeding and then the infant seemed efficient in reducing the risk of AE.^{160,163}

9 | HOT TOPIC—ATOPIC ECZEMA AND SARS-COV-2

In the context of the Corona pandemic, it is of interest that especially one known SARS-CoV-2 receptor, CD147 and its related molecules, are expressed higher in lesions of AE patients than healthy controls and could hint towards a predisposition towards SARS-CoV-2 infections.¹⁶⁴ However, allergy was not identified as risk factor for bad COVID-19 outcome in children.¹⁶⁵ Therefore, it is advised for AE patients to continue immune-modulating treatments.^{166,167} Also, COVID-19 vaccinations are recommended for AE patients without pausing medication before or after vaccination.¹⁶⁸

10 | CONCLUSION

Atopic dermatitis is a complex skin disease with underlying skin barrier defects. Multiple intrinsic but also extrinsic factors put humans at risk to develop AE—among them environmental factors which in times of climate change could play an even stronger role in future. However, the heterogenous disease can be divided into multiple endotypes with different pathomechanisms. Therefore, a personalized medicine approach for an effective management of AE is needed. New strategies emerged in the last years, tackling the skin barrier including the microbiome or factors of the immune system. Even better would be the prevention of AE, possibly by suitable emollients or pre- and probiotics, as AE is known and confirmed to be the first step of the atopic march. Many parts of the complex disease mechanisms could be unravelled in the last decades. However, much is still unknown and must be addressed by the science community, particularly host-microbe and environmental interaction.

ACKNOWLEDGEMENT

We would like to thank Ania Globinska for her great support with the figures.

CONFLICT OF INTEREST

CH reports grants from Beiersdorf, Germany and Sebapharma, Germany, outside the submitted work. ABW reports personal fees from Novartis Pharma, Germany, Takeda Pharma, Germany. CTH reports personal fees from Novartis, Germany, Sanofi, Germany, Lilly pharma, Germany, Bencard, Germany, Danone nutricia, Lancome, Germany, L'oreal, Germany, grants and personal fees from Töpfer GmbH, and Beiersdorf AG, Germany, outside the submitted work. MR reports personal fees from Bencard, Germany, Roche-Posay, Germany, Galderma, Germany, Sebapharma, Germany, grants from CLR, Germany, and Beiersdorf, Germany, outside the submitted work.

ORCID

Claudia Hülpüsch  <https://orcid.org/0000-0002-5711-1356>

Andreas B. Weins  <https://orcid.org/0000-0002-0982-7122>

Claudia Traidl-Hoffmann  <https://orcid.org/0000-0001-5085-5179>

Matthias Reiger  <https://orcid.org/0000-0002-6173-2104>

REFERENCES

1. Eyerich S, Eyerich K, Traidl-Hoffmann C, Biedermann T. Cutaneous barriers and skin immunity: Differentiating a connected network. *Trends Immunol.* 2018;39(4):315-327.
2. Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2016;138(2):336-349.
3. Bieber T, D'Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? *J Allergy Clin Immunol.* 2017;139(4s):S58-s64.
4. Lauffer F, Baghin V, Standl M, et al. Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. *Allergy.* 2021;76(4):1158-1172.
5. Czarnewicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J Allergy Clin Immunol.* 2019;143(1):1-11.
6. Zeiser K, Hammel G, Kirchberger I, Traidl-Hoffmann C. Social and psychosocial effects on atopic eczema symptom severity – a scoping review of observational studies published from 1989 to 2019. *J Eur Acad Dermatol Venereol.* 2021;35(4):835-843.
7. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. *Allergy.* 2018;73(6):1284-1293.
8. Kowalska-Oledzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. *J Drug Assess.* 2019;8(1):126-128.
9. Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. *J Dermatolog Treat.* 2020;31(8):801-809.
10. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. *J Invest Dermatol* 2017;137(1):26-30.
11. Silverberg JI. Public Health Burden and Epidemiology of Atopic Dermatitis. *Dermatol Clin* 2017;35(3):283-289.
12. Sasaki M, Morikawa E, Yoshida K, Adachi Y, Odajima H, Akasawa A. The change in the prevalence of wheeze, eczema and rhinoconjunctivitis among Japanese children: Findings from 3 nationwide cross-sectional surveys between 2005 and 2015. *Allergy.* 2019;74(8):1572-1575.
13. Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways. *J Allergy Clin Immunol.* 2019;143(1):46-55.
14. Zuberbier T, Lötvall J, Simoons S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. *Allergy.* 2014;69(10):1275-1279.
15. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. *Acta Derm Venereol.* 2020;100(12):adv00160.
16. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. *Expert Rev Clin Immunol.* 2017;13(1):15-26.
17. Traidl-Hoffmann C. Allergy - an environmental disease. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2017;60(6):584-591.
18. Gilles S, Akdis C, Lauener R, et al. The role of environmental factors in allergy: A critical reappraisal. *Exp Dermatol.* 2018;27(11):1193-1200.
19. Heuson C, Traidl-Hoffmann C. The significance of climate and environment protection for health under special consideration of skin barrier damages and allergic sequelae. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2018;61(6):684-696.
20. Alkotob SS, Cannedy C, Harter K, et al. Advances and novel developments in environmental influences on the development of atopic diseases. *Allergy.* 2020;75(12):3077-3086.
21. Hale G, Davies E, Grindlay DJC, Rogers NK, Harman KE. What's new in atopic eczema? An analysis of systematic reviews published

- in 2017. Part 2: epidemiology, aetiology and risk factors. *Clin Exp Dermatol*. 2019;44(8):868-873.
22. Boutin RCT, Sbihi H, Dsouza M, et al. Mining the infant gut microbiota for therapeutic targets against atopic disease. *Allergy*. 2020;75(8):2065-2068.
 23. Venter C, Meyer RW, Nwaru BI, et al. EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. *Allergy*. 2019;74(8):1429-1444.
 24. Chang YS, Weng SF, Wang JJ, et al. Association between keratoconus and the risk of adolescent- or adult-onset atopic dermatitis. *Allergy*. 2020;75(11):2946-2948.
 25. Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2016;75(6):1119-1125.e1111.
 26. Haahtela T, Holgate S, Pawankar R, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. *World Allergy Organ J*. 2013;6(1):3.
 27. Haahtela T. A biodiversity hypothesis. *Allergy*. 2019;74(8):1445-1456.
 28. Rook GAW. A Darwinian View of the Hygiene or "Old Friends" Hypothesis. *Microbe Magazine*. 2012;7(4):173-180.
 29. Walter J, O'Mahony L. The importance of social networks-An ecological and evolutionary framework to explain the role of microbes in the aetiology of allergy and asthma. *Allergy*. 2019;74(11):2248-2251.
 30. Xu F, Yan S, Li F, et al. Prevalence of childhood atopic dermatitis: an urban and rural community-based study in Shanghai, China. *PLoS One*. 2012;7(5):e36174.
 31. Chatenoud L, Bertuccio P, Turati F, et al. Markers of microbial exposure lower the incidence of atopic dermatitis. *Allergy*. 2020;75(1):104-115.
 32. Thyssen JP, Ahluwalia TS, Paternoster L, et al. Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis. *Allergy*. 2020;75(6):1481-1485.
 33. Marrs T, Logan K, Craven J, et al. Dog ownership at three months of age is associated with protection against food allergy. *Allergy*. 2019;74(11):2212-2219.
 34. Skajaa N, Nissen TN, Birk NM, Jeppesen DL, Thøstesen LM, Benn CS. Cesarean delivery and risk of atopic dermatitis. *Allergy*. 2020;75(5):1229-1231.
 35. Dimitriu PA, Iker B, Malik K, Leung H, Mohn WW, Hillebrand GG. New Insights into the Intrinsic and Extrinsic Factors That Shape the Human Skin Microbiome. *MBio*. 2019;10(4):1-14.
 36. Fairweather V, Hertig E, Traidl-Hoffmann C. A brief introduction to climate change and health. *Allergy*. 2020;75(9):2352-2354.
 37. Murota H, Yamaga K, Ono E, Katayama I. Sweat in the pathogenesis of atopic dermatitis. *Allergol Int*. 2018;67(4):455-459.
 38. Danby SG, Brown K, Wigley AM, et al. The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. *J Invest Dermatol*. 2018;138(1):68-77.
 39. Dickel H, Kuhlmann L, Bauer A, et al. Atopy patch testing with aeroallergens in a large clinical population of dermatitis patients in Germany and Switzerland, 2000-2015: a retrospective multi-centre study. *J Eur Acad Dermatol Venereol*. 2020;34(9):2086-2095.
 40. Hassoun Y, James C, Bernstein DI. The effects of air pollution on the development of atopic disease. *Clin Rev Allergy Immunol*. 2019;57(3):403-414.
 41. Ahn K. The role of air pollutants in atopic dermatitis. *J Allergy Clin Immunol*. 2014;134(5):993-999.
 42. Kabashima K, Otsuka A, Nomura T. Linking air pollution to atopic dermatitis. *Nat Immunol*. 2017;18(1):5-6.
 43. Wang HL, Sun J, Qian ZM, et al. Association between air pollution and atopic dermatitis in Guangzhou, China: modification by age and season. *Br J Dermatol*. 2020;184(6):1068-1076.
 44. Raap U & Schmid-Ott G. Psychological Factors of Atopic Dermatitis. In *Pediatric and Adolescent Medicine*. 2011;50-55. <https://doi.org/10.1159/000328167>
 45. Raap U, Werfel T, Jaeger B, Schmid-Ott G. Atopic dermatitis and psychological stress. *Hautarzt*. 2003;54(10):925-929. <https://doi.org/10.1007/s00105-003-0609-z>
 46. Chida Y, Steptoe A, Hiraoka N, Sudo N, Kubo C. The effects of psychological intervention on atopic dermatitis. A systematic review and meta-analysis. *Int Arch Allergy Immunol*. 2007;144(1):1-9.
 47. Harter K, Hammel G, Krabiell L, et al. Different Psychosocial Factors Are Associated with Seasonal and Perennial Allergies in Adults: Cross-Sectional Results of the KORA FF4 Study. *Int Arch Allergy Immunol*. 2019;179(4):262-272.
 48. Lee E, Lee SH, Kwon JW, et al. Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. *Allergy*. 2016;71(5):692-700.
 49. Mortz CG, Andersen KE, Poulsen LK, Kjaer HF, Broesby-Olsen S, Bindslev-Jensen C. Atopic diseases and type I sensitization from adolescence to adulthood in an unselected population (TOACS) with focus on predictors for allergic rhinitis. *Allergy*. 2019;74(2):308-317.
 50. Toppila-Salmi S, Chanoine S, Karjalainen J, Pekkanen J, Bousquet J, Siroux V. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. *Allergy*. 2019;74(12):2406-2416.
 51. Brough HA, Nadeau KC, Sindher SB, et al. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? *Allergy*. 2020;75(9):2185-2205.
 52. Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents. *Allergy*. 2020;75(12):3248-3260.
 53. Martin MJ, Estravís M, García-Sánchez A, Dávila I, Isidoro-García M, Sanz C. Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review. *Genes (Basel)*. 2020;11(4):442.
 54. Saunders SP, Floudas A, Moran T, et al. Dysregulated skin barrier function in Tmem79 mutant mice promotes IL-17A-dependent spontaneous skin and lung inflammation. *Allergy*. 2020;75(12):3216-3227.
 55. Schwartz C, Moran T, Saunders SP, et al. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1 β . *Allergy*. 2019;74(10):1920-1933.
 56. Rahrhig S, Dettmann JM, Brauns B, et al. Transient epidermal barrier deficiency and lowered allergic threshold in filaggrin-hornorin (FlgHnr(-/-)) double-deficient mice. *Allergy*. 2019;74(7):1327-1339.
 57. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet*. 2006;38(4):441-446.
 58. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol*. 2013;131(2):280-291.
 59. Danby SG & Cork MJ. pH in Atopic Dermatitis. In *Current Problems in Dermatology*. 2018;95-107. <https://doi.org/10.1159/000489523>
 60. Ali SM, Yosipovitch G. Skin pH: from basic science to basic skin care. *Acta Derm Venereol*. 2013;93(3):261-267.
 61. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. *J Invest Dermatol*. 2003;121(2):345-353.
 62. Jang H, Matsuda A, Jung K, et al. Skin pH Is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model. *J Invest Dermatol*. 2016;136(1):127-135.
 63. Ramesh K, Matta SA, Chew FT, Mok YK. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type

- related inhibitor action and enhance its degradation. *Allergy*. 2020;75(2):403-411.
64. Baurecht H, Rühlemann MC, Rodríguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. *J Allergy Clin Immunol*. 2018;141(5):1668-1676.
 65. Boer DEC, van Smeden J, Al-Khakany H, et al. Skin of atopic dermatitis patients shows disturbed β -glucocerebrosidase and acid sphingomyelinase activity that relates to changes in stratum corneum lipid composition. *Biochimica et Biophysica Acta*. 2020;1865(6):158673.
 66. Seiti Yamada Yoshikawa F, Feitosa de Lima J, Notomi Sato M, Álefe Leuzzi Ramos Y, Aoki V, Leao OR. Exploring the Role of Staphylococcus Aureus Toxins in Atopic Dermatitis. *Toxins* 2019;11(6):321.
 67. Hülpüsch C, Tremmel K, Hammel G, et al. Skin pH-dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity. *Allergy*. 2020;75(11):2888-2898.
 68. Elias PM. The skin barrier as an innate immune element. *Semin Immunopathol*. 2007;29(1):3-14.
 69. Ottman N, Barrientos-Somarrivas M, Fyhrquist N, et al. Microbial and transcriptional differences elucidate atopic dermatitis heterogeneity across skin sites. *Allergy*. 2021;76(4):1173-1187.
 70. Gonzalez T, Stevens ML, Baatrebekkyzy A, et al. Biofilm propensity of Staphylococcus aureus skin isolates is associated with increased atopic dermatitis severity and barrier dysfunction in the MPAACH pediatric cohort. *Allergy*. 2021;76(1):302-313.
 71. Di Domenico EG, Cavallo I, Bordignon V, et al. Inflammatory cytokines and biofilm production sustain Staphylococcus aureus outgrowth and persistence: a pivotal interplay in the pathogenesis of Atopic Dermatitis. *Sci Rep*. 2018;8(1):9573.
 72. Krysko O, Teufelberger A, Van Nevel S, Krysko DV, Bachert C. Protease/antiprotease network in allergy: The role of Staphylococcus aureus protease-like proteins. *Allergy*. 2019;74(11):2077-2086.
 73. Lacoma A, Edwards AM, Young BC, Domínguez J, Prat C, Laabei M. Cigarette smoke exposure redirects Staphylococcus aureus to a virulence profile associated with persistent infection. *Sci Rep*. 2019;9(1):10798.
 74. Oetjen LK, Kim BS. Interactions of the immune and sensory nervous systems in atopy. *Febs J*. 2018;285(17):3138-3151.
 75. Guseva D, Rüdrieh U, Kotnik N, et al. Neuronal branching of sensory neurons is associated with BDNF-positive eosinophils in atopic dermatitis. *Clin Exp Allergy*. 2020;50(5):577-584.
 76. Roesner LM, Werfel T, Heratizadeh A. The adaptive immune system in atopic dermatitis and implications on therapy. *Expert Rev Clin Immunol*. 2016;12(7):787-796.
 77. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. *J Allergy Clin Immunol*. 2017;139(4s):S65-S76.
 78. Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. *Allergy*. 2020;75(3):546-560.
 79. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy*. 2020;75(1):54-62.
 80. Brulefert A, Hoste A, Muller Q, Fauny JD, Mueller CG, Flacher V. Vitamin D3-elicited CD14⁺ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses. *Allergy*. 2021;76(7):2044-2056.
 81. Yamanishi Y, Mogi K, Takahashi K, Miyake K, Yoshikawa S, Karasuyama H. Skin-infiltrating basophils promote atopic dermatitis-like inflammation via IL-4 production in mice. *Allergy*. 2020;75(10):2613-2622.
 82. Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. *J Dermatol*. 2015;42(2):129-139.
 83. Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H(4) receptor antagonist ZPL-3893787 in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2019;143(5):1830-1837.
 84. Schaper-Gerhardt K, Köther B, Wolff L, et al. The H(4) R is highly expressed on eosinophils from AD patients and IL-4 upregulates expression and function via the JAK/STAT pathway. *Allergy*. 2021;76(4):1261-1264.
 85. Karra L, Gangwar RS, Puzovio PG, et al. CD300a expression is modulated in atopic dermatitis and could influence the inflammatory response. *Allergy*. 2019;74(7):1377-1380.
 86. Coates M, Lee MJ, Norton D, MacLeod AS. The Skin and Intestinal Microbiota and Their Specific Innate Immune Systems. *Front Immunol*. 2019;10:2950.
 87. Ong PY, Ohtake T, Brandt C, et al. Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis. *N Engl J Med*. 2002;347(15):1151-1160.
 88. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. *J Invest Dermatol*. 2005;125(6):1163-1173.
 89. Rieg S, Steffen H, Seeber S, et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. *J Immunol*. 2005;174(12):8003-8010.
 90. Nguyen HLT, Trujillo-Paez JV, Umehara Y, et al. Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis. *Int J Mol Sci*. 2020;21(20):7607.
 91. Maintz L, Novak N. Modifications of the innate immune system in atopic dermatitis. *J Innate Immun*. 2011;3(2):131-141.
 92. Novak N, Yu CF, Bussmann C, et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. *Allergy*. 2007;62(7):766-772.
 93. Skabytska Y, Kaesler S, Volz T, Biedermann T. How the innate immune system trains immunity: lessons from studying atopic dermatitis and cutaneous bacteria. *J der Deutschen Dermatologischen Gesellschaft*. 2016;14(2):153-156.
 94. Moriwaki M, Iwamoto K, Niitsu Y, et al. Staphylococcus aureus from atopic dermatitis skin accumulates in the lysosomes of keratinocytes with induction of IL-1 α secretion via TLR9. *Allergy*. 2019;74(3):560-571.
 95. Meyer TC, Michalik S, Holtfreter S, et al. A Comprehensive View on the Human Antibody Repertoire Against Staphylococcus aureus Antigens in the General Population. *Front Immunol*. 2021;12:651619.
 96. Reginald K, Westritschnig K, Linhart B, et al. Staphylococcus aureus fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses. *J Allergy Clin Immunol*. 2011;128(1):82-91.
 97. Bunikowski R, Mielke M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. *J Allergy Clinical Immunol*. 1999;103(1):119-124.
 98. Teymournejad O, Montgomery CP. Evasion of Immunological Memory by S. aureus Infection: Implications for Vaccine Design. *Front Immunol* 2021;12:633672.
 99. Janmohamed SR, Grosber M, Eichenfield LF, Ring J, Gutermuth J. Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I). *Allergy*. 2021;76(1):403-406.
 100. Jacob M, Bin Khalaf D, Alhissi S, et al. Quantitative profiling of cytokines and chemokines in DOCK8-deficient and atopic dermatitis patients. *Allergy*. 2019;74(2):370-379.
 101. Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. *Ann Allergy Asthma Immunol*. 2017;119(5):435-440.
 102. Darrigade AS, Colmant C, de Montjoye L, et al. Atopic Dermatitis Score 7 (ADS7): A promising tool for daily clinical assessment of atopic dermatitis. *Allergy*. 2020;75(5):1264-1266.

103. Nouwen AEM, Karadavut D, Pasmans S, et al. Natural moisturizing factor as a clinical marker in atopic dermatitis. *Allergy*. 2020;75(1):188-190.
104. Rinaldi AO, Morita H, Wawrzyniak P, et al. Direct assessment of skin epithelial barrier by electrical impedance spectroscopy. *Allergy*. 2019;74(10):1934-1944.
105. Rinaldi AO, Korsfeldt A, Ward S, et al. Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis. *Allergy*. 2021. <https://doi.org/10.1111/all.14842>. [Epub ahead of print].
106. Sun Z, Huang S, Zhu P, et al. A Microbiome-Based Index for Assessing Skin Health and Treatment Effects for Atopic Dermatitis in Children. *mSystems*. 2019;4(4):e00293.
107. Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2019;143(1):26-35.
108. Kong HH, Andersson B, Clavel T, et al. Performing Skin Microbiome Research: A Method to the Madness. *J Invest Dermatol*. 2017;137(3):561-568.
109. Thijs JL, Fiechter R, Giovannone B, et al. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity. *Allergy*. 2019;74(11):2240-2243.
110. Thijs JL, Drylewicz J, Bruijnzeel-Koomen C, et al. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A. *Allergy*. 2019;74(3):613-617.
111. Bakker DS, Ariens LFM, Giovannone B, et al. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. *Allergy*. 2020;75(12):3287-3289.
112. Chen S, Ghandikota S, Gautam Y, Mersha TB. AllergyGenDB: A literature and functional annotation-based omics database for allergic diseases. *Allergy*. 2020;75(7):1789-1793.
113. Baumann R, Untermayr E, Zissler UM, et al. Non-invasive and minimally-invasive techniques for the diagnosis and management of allergic diseases. *Allergy*. 2021;76(4):1010-1023.
114. Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in non-lesional skin. *Allergy*. 2021;76(1):314-325.
115. Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. *Allergy*. 2020;75(12):3039-3068.
116. Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. *J Allergy Clin Immunol*. 2020;145(1):215-228.
117. Werfel THA, Aberer W, Ahrens F, et al. "Systemic treatment of atopic dermatitis" of the S2k-guideline on atopic dermatitis. *J Dtsch Dermatol Ges*. 2021;19(1):151-168.
118. Looman KIM, van Meel ER, Grosserichter-Wagener C, et al. Associations of Th2, Th17, Treg cells, and IgA(+) memory B cells with atopic disease in children: The Generation R Study. *Allergy*. 2020;75(1):178-187.
119. Avena-Woods C. Overview of atopic dermatitis. *Am J Manag Care*. 2017;23(8 Suppl):S115-s123.
120. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*. 2018;32(5):657-682.
121. Nakahara T, Fujita H, Arima K, Taguchi Y, Motoyama S, Furue M. Treatment satisfaction in atopic dermatitis relates to patient-reported severity: A cross-sectional study. *Allergy*. 2019;74(6):1179-1181.
122. Sindher S, Alkotob SS, Shojinaga MN, et al. Pilot study measuring transepidermal water loss (TEWL) in children suggests trilipid cream is more effective than a paraffin-based emollient. *Allergy*. 2020;75(10):2662-2664.
123. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and *Staphylococcus aureus* in atopic dermatitis. *J Am Acad Dermatol*. 1992;27(1):29-34.
124. Gonzalez ME, Schaffer JV, Orlow SJ, et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. *J Am Acad Dermatol*. 2016;75(3):481-493.
125. Blanchet-Réthoré S, Bourdès V, Mercenier A, Haddar CH, Verhoeven PO, Andres P. Effect of a lotion containing the heat-treated probiotic strain *Lactobacillus johnsonii* NCC 533 on *Staphylococcus aureus* colonization in atopic dermatitis. *Clin Cosmet Investig Dermatol*. 2017;10:249-257.
126. Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with *Roseomonas mucosa* for atopic dermatitis. *JCI Insight*. 2018;3(9). <https://doi.org/10.1172/jci.insight.120608>
127. Parlet CP, Brown MM, Horswill AR. Commensal *Staphylococci* Influence *Staphylococcus aureus* Skin Colonization and Disease. *Trends Microbiol*. 2019;27(6):497-507.
128. Williams MR, Costa SK, Zaramela LS, et al. Quorum sensing between bacterial species on the skin protects against epidermal injury in atopic dermatitis. *Sci Transl Med*. 2019;11(490):eaat8329.
129. Paharik AE, Parlet CP, Chung N, et al. Coagulase-Negative *Staphylococcal* Strain Prevents *Staphylococcus aureus* Colonization and Skin Infection by Blocking Quorum Sensing. *Cell Host Microbe*. 2017;22(6):746-756.
130. Luu LA, Flowers RH, Kellams AL, et al. Apple cider vinegar soaks [0.5%] as a treatment for atopic dermatitis do not improve skin barrier integrity. *Pediatr Dermatol*. 2019;36(5):634-639.
131. Sawada Y, Tong Y, Barangi M, et al. Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro. *J Allergy Clin Immunol*. 2019;143(5):1946-1948.
132. Silva SH, Guedes AC, Gontijo B, et al. Influence of narrow-band UVB phototherapy on cutaneous microbiota of children with atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2006;20(9):1114-1120.
133. Clowry J, Irvine AD, McLoughlin RM. Next-generation anti-*Staphylococcus aureus* vaccines: A potential new therapeutic option for atopic dermatitis? *J Allergy Clin Immunol*. 2019;143(1):78-81.
134. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol*. 2018;32(6):850-878.
135. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. *Allergy*. 2021;76(4):1053-1076.
136. Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. *Drugs*. 2020;80(11):1041-1052.
137. Ahn J, Choi Y, Simpson EL. Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules. *Ann Dermatol*. 2021;33(2):101-107.
138. Ahn J, Choi Y, Simpson EL. Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics. *Ann Dermatol*. 2021;33(1):1-10.
139. Matteredne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. *Cochrane Database Syst Rev*. 2019;1(1):Cd012167.
140. Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Matteredne U, Weisshaar E. Oral H1 antihistamines as monotherapy for eczema. *Cochrane Database Syst Rev*. 2013;2013(2):Cd007770.
141. Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. *Immunol Allergy Clin North Am*. 2017;37(1):113-122.
142. Wegner J, Saloga J, Grabbe S, et al. IgE-specific immunoadsorption: New treatment option for severe refractory atopic dermatitis. *Allergy*. 2019;74(6):1190-1193.
143. Chu H, Park KH, Kim SM, et al. Allergen-specific immunotherapy for patients with atopic dermatitis sensitized to animal dander. *Immun Inflamm Dis*. 2020;8(2):165-169.
144. Weidner J, Bartel S, Kılıç A, et al. Spotlight on microRNAs in allergy and asthma. *Allergy*. 2021;76(6):1661-1678.

145. Vaher H, Runnel T, Urgard E, et al. miR-10a-5p is increased in atopic dermatitis and has capacity to inhibit keratinocyte proliferation. *Allergy*. 2019;74(11):2146-2156.
146. Hayashi K, Kaminuma O, Nishimura T, et al. LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation. *Allergy*. 2020;75(2):463-467.
147. Bieber T, Traidl-Hoffmann C, Schäppi G, Lauener R, Akdis C, Schmid-Grendlmeier P. Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine. *Allergy*. 2020;75(11):2936-2938.
148. Perrett KP, Peters RL. Emollients for prevention of atopic dermatitis in infancy. *Lancet*. 2020;395(10228):923-924.
149. Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *The Lancet*. 2020;395(10228):951-961.
150. Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. *Lancet*. 2020;395(10228):962-972.
151. Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. *J Allergy Clin Immunol*. 2014;134(4):824-830.
152. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J Allergy Clin Immunol*. 2014;134(4):818-823.
153. Kothari A, Locke A, Eiwegger T. Emollients for the prevention of atopic dermatitis. *Allergy*. 2021;76(8):2641-2643.
154. Lack G, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. *N Engl J Med*. 2003;348(11):977-985.
155. Nicklaus S, Divaret-Chauveau A, Chardon ML, et al. The protective effect of cheese consumption at 18 months on allergic diseases in the first 6 years. *Allergy*. 2019;74(4):788-798.
156. Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma. *Allergy*. 2020;75(3):497-523.
157. Rusu E, Enache G, Cursaru R, et al. Prebiotics and probiotics in atopic dermatitis. *Exp Ther Med*. 2019;18(2):926-931.
158. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr*. 1995;125(6):1401-1412.
159. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11(8):506-514.
160. Amalia N, Orchard D, Francis KL, King E. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. *Australas J Dermatol*. 2020;61(2):e158-e173.
161. Roßberg S, Keller T, Icke K, et al. Orally applied bacterial lysate in infants at risk for atopy does not prevent atopic dermatitis, allergic rhinitis, asthma or allergic sensitization at school age: Follow-up of a randomized trial. *Allergy*. 2020;75(8):2020-2025.
162. Garcia-Larsen V, Ierodiakonou D, Jarrold K, et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: A systematic review and meta-analysis. *PLoS Med*. 2018;15(2):e1002507.
163. Li L, Han Z, Niu X, et al. Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-analysis. *Am J Clin Dermatol*. 2019;20(3):367-377.
164. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. *Allergy*. 2020;75(11):2829-2845.
165. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy*. 2021;76(2):510-532.
166. Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologics for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. *Allergy*. 2020;75(11):2764-2774.
167. Wollenberg A, Flohr C, Simon D, et al. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2020;34(6):e241-e242.
168. Thyssen JP, Vestergaard C, Barbarot S, et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. *J Eur Acad Dermatol Venereol*. 2021;35(5):e308-e311.

How to cite this article: Hülpüsch C, Weins AB, Traidl-Hoffmann C, Reiger M. A new era of atopic eczema research: Advances and highlights. *Allergy*. 2021;00:1-14. <https://doi.org/10.1111/all.15058>